Status:
COMPLETED
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
Lead Sponsor:
Laval University
Conditions:
Overweight
Microtia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Previous work of the investigators demonstrated the anti-obesity and anti-steatosis potential of the Amazonian fruit camu-camu (CC) in a mouse model of diet-induced obesity \[1\]. It was demonstrated ...
Eligibility Criteria
Inclusion
- BMI between 25 and 40 kg/m2
- Fasting triglyceride \> 1,35 mmol/L
- Understanding of spoken and written french
- Accept to follow study instructions
Exclusion
- Smoking
- Medication affecting glucose metabolism, blood lipid levels or blood pressure
- Metabolic disorders requiring treatment
- Diabetic subjects presenting HbA1c \>6.5% or fasting glycemia \>7 mmol/L
- Consumption of fruit or polyphenol supplements in the last 3 months
- Allergy or intolerance for camu camu or for an ingredient of the placebo
- Alcohol consumption of \> 2 drinks / day
- Weight change \> 5% of body weight in the last 3 months
- Major surgical operation in the last 3 months or planned in the next months
- Pregnant or breastfeeding women or women planning pregnancy in the next months
- Antibiotics intake in the last 3 months
- Regular probiotics intake in the last 3 months
- Gastrointestinal malabsorption
- Cirrhosis
- Chronic kidney disease
- Concomitant participation in another clinical trial
Key Trial Info
Start Date :
October 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 21 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04130321
Start Date
October 31 2020
End Date
April 21 2022
Last Update
October 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
INAF, Université Laval
Québec, Canada, G1V 0A6